No connection

Search Results

PLSM vs TXMD

PLSM
Pulsenmore Ltd.
BEARISH
Price
$3.65
Market Cap
$23.7M
Sector
Healthcare
AI Confidence
85%
TXMD
TherapeuticsMD, Inc.
BEARISH
Price
$2.18
Market Cap
$25.2M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
PLSM
--
TXMD
--
Forward P/E
PLSM
--
TXMD
6.23
P/B Ratio
PLSM
--
TXMD
0.94
P/S Ratio
PLSM
--
TXMD
8.35
EV/EBITDA
PLSM
--
TXMD
-12.03

Profitability

Gross Margin
PLSM
84.16%
TXMD
100.0%
Operating Margin
PLSM
0.0%
TXMD
-108.51%
Profit Margin
PLSM
-39.61%
TXMD
-18.83%
ROE
PLSM
-17.62%
TXMD
-2.41%
ROA
PLSM
-6.24%
TXMD
-3.87%

Growth

Revenue Growth
PLSM
578.3%
TXMD
33.9%
Earnings Growth
PLSM
--
TXMD
--

Financial Health

Debt/Equity
PLSM
0.02
TXMD
0.23
Current Ratio
PLSM
7.88
TXMD
3.02
Quick Ratio
PLSM
7.17
TXMD
2.44

Dividends

Dividend Yield
PLSM
--
TXMD
--
Payout Ratio
PLSM
0.0%
TXMD
0.0%

AI Verdict

PLSM BEARISH

PLSM exhibits severe fundamental weakness as evidenced by a Piotroski F-Score of 2/9, placing it in the 'Weak' health category. While the company shows explosive top-line revenue growth of 578.30% and impressive gross margins of 84.16%, it is unable to translate this into profitability, with a profit margin of -39.61%. The technical trend is completely bearish (0/100) with a 50.4% decline over the past year. Despite a very strong liquidity position (Current Ratio 7.88), the lack of earnings and poor financial health scores make this a high-risk speculative asset.

Strengths
Hyper-growth revenue increase of 578.30% YoY
Strong gross profit margins at 84.16%
Extremely low leverage with a Debt/Equity ratio of 0.02
Risks
Critical financial health weakness (Piotroski F-Score 2/9)
Significant negative profit margins (-39.61%)
Severe bearish price momentum (-50.4% 1Y change)
TXMD BEARISH

TXMD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 33.9% and maintains a healthy current ratio of 3.02, these are offset by a disastrous operating margin of -108.51% and a 5-year price collapse of -96.5%. The stock is currently trading near its book value (P/B 0.94), but the lack of consistent profitability and a history of volatile earnings surprises make it a high-risk speculative play.

Strengths
Strong YoY revenue growth of 33.90%
Robust liquidity with a current ratio of 3.02
Low leverage with a Debt/Equity ratio of 0.23
Risks
Critically low Piotroski F-Score (2/9) signaling fundamental decay
Severe operational losses with an operating margin of -108.51%
Extreme long-term value destruction (-96.5% 5-year change)

Compare Another Pair

PLSM vs TXMD: Head-to-Head Comparison

This page compares Pulsenmore Ltd. (PLSM) and TherapeuticsMD, Inc. (TXMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile